John Alexander Kelly, serving as Chief Financial Officer for Precision Biosciences Inc (NASDAQ: DTIL), carried out the sale of 15,213 shares of common stock on January 21, 2026. These shares were sold at a price of $4.03, generating total proceeds of approximately $61,308. This transaction occurred while DTIL shares were trading slightly higher than the sale price, at $4.25, marking an increase from the prior session's close of $4.01. Despite this brief uptick, the stock has experienced a decline nearing 14% over the last six months.
Notably, a day earlier on January 20, 2026, Kelly added to his holdings by receiving a total of 44,363 shares through the vesting of Restricted Stock Units (RSUs). These shares were granted across three tranches involving 3,888, 13,900, and 26,575 shares respectively. Following these exchanges, Kelly’s direct ownership stake in Precision Biosciences totals 106,448 shares.
Relevant financial data indicates that the biotechnology firm, with a current market capitalization near $102 million, maintains a balance sheet featuring more cash than debt, according to data from InvestingPro. Despite this, InvestingPro rates the financial health of Precision Biosciences as 'WEAK'. The company is assessed to be trading above its estimated Fair Value, suggesting that current market prices may not fully reflect intrinsic valuation.
In parallel with these insider transactions, Precision Biosciences is advancing several key initiatives in its research and development pipeline. The company is actively conducting multiple dosing cohorts as part of its Phase 1/2a ELIMINATE-B clinical trial focused on chronic hepatitis B infection. Additionally, Precision anticipates achieving regulatory approval to commence its program targeting Duchenne muscular dystrophy within the first quarter of 2026.
As of the end of 2025, the company reported having approximately $137 million in unaudited cash and cash equivalents, which it believes will be sufficient to support key data milestones through 2028. In support of its ongoing programs, Precision Biosciences has also announced a stock and warrant offering aiming to raise around $75 million in gross proceeds. This financial effort involves issuing over 10.8 million shares and warrants, including pre-funded warrants targeted at particular investors.
At the recent American Association for the Study of Liver Diseases conference, the company presented promising findings from its Phase 1 ELIMINATE-B study. This study assessed PBGENE-HBV, an investigational gene editing therapy addressing chronic Hepatitis B. Data showed dose-dependent antiviral effects in all nine patients involved in the initial cohorts, underscoring the potential impact of this approach.